GlassScriptPhysician profile
Chandra D Payne
NPI 1558475731
$7,534.33
in general payments reported to CMS, 2019-2025
42 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,426 · 2022: $1,749 · 2023: $1,541 · 2024: $1,383 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,358.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,531.48 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,085.09 | 2022-2025 | |
| Pfizer INC. | $792.48 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.79 | 2021-2024 | Jardiance, Ofev, Synjardy |
| Lilly USA, LLC | $381.45 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $334.46 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $300.93 | 2021-2024 | Trintellix |
| Amgen INC. | $265.08 | 2021-2025 | Repatha, Otezla, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $261.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $254.72 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $254.25 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $149.39 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $128.15 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $105.48 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $101.84 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.